Government lawyers used airline executives’ own words in trying Tuesday to persuade a federal judge to kill a partnership between American Airlines and JetBlue Airways.

The government argued that the deal is, in effect, a merger that will cost consumers $700 million a year in higher fares. It said JetBlue’s pending purchase of Spirit Airlines will make matters even worse for travelers.

JetBlue CEO Robin Hayes was the first witness in the trial in federal district court in Boston over the federal government’s antitrust lawsuit against American and JetBlue. The airlines are coordinating schedules and sharing revenue from flights in the Northeast, including New York-area airports.

Hayes was quizzed about his own previous statements criticizing joint ventures involving other airlines and a 2019 comment that the airline industry “has never been more concentrated than it is today,” which he said led to higher fares and poor service.

Hayes testified that regulators had not imposed enough limits on those deals. He contrasted them with the pact between American and JetBlue, which he said involved no cooperation on setting prices.

In another 2019 memo, an American Airlines executive vowed that his company would fight JetBlue for supremacy in Boston — even using a metaphor of swinging baseball bats.

“We know how the story ends,” said William Jones, the lead attorney for the Justice Department. “Rather than continuing to slug it out, American and JetBlue decided to collaborate rather than to continue competing.”

Lawyers for American and JetBlue countered that the government has presented no evidence that their alliance — in place for 18 months now, since it was blessed by the outgoing Trump administration — has harmed consumers or resulted in higher fares. They said that it has allowed the airlines to add 50 new routes and create a stronger competitor to Delta and United.

The airlines’ lawyers said that the Justice Department sued prematurely instead of taking a wait-and-see approach.

“Most cases don’t get brought until there is some tangible evidence that the practices are doing harm,” said Daniel Wall, a San Francisco lawyer who is leading American’s defense.

Wall challenged the government’s claim that previous airline mergers — about a half dozen over the last two decades — have led to higher prices.

Transportation Department data from the first quarter shows that the national average fare declined 29% in the last 10 years and 36% in the last 20 years, after adjusting for inflation. While consolidation has eliminated famous aviation names such as TWA, Continental and Northwest, new low-fare airlines — including JetBlue — have pushed fares lower over that period.

The Justice Department and six states that have joined its lawsuit plan to call a Georgetown University economist who will testify that the American-JetBlue deal will reduce competition and cost consumers $700 million a year.

“And it stands potentially to get worse with JetBlue’s announced acquisition of Spirit Airlines,” Jones said.

The Justice Department is currently examining JetBlue’s proposed $3.8 billion purchase of Spirit. Jones’ comments indicate that regulators could take a dim view of the acquisition, which would mean the end of Spirit, the nation’s biggest discount airline.

The Biden administration has pushed to aggressively enforce antitrust laws, but it lost two major cases last week. The Justice Department failed in bids to block a merger of two big sugar refiners and an acquisition by health insurer UnitedHealth Group.

Associated Press writer Marcy Gordon in Washington, DC, contributed to this report.

The post JetBlue CEO first witness in U.S. lawsuit in opposition to 2 airways appeared first on Los Gatos News And Events.

With a storied, celebrity past and almost a century of careful preservation paired with with high-end, careful renovation, 2500 Divisadero is a San Francisco legend. You could write the next chapter for this historic mansion, on the market now for $15.995 million.

This 9,125 square-foot home was built in 1933 by locally renowned architect Angus McSweeny, a partner in Willis, Polk, and Company, an architectural partnership that produced hundreds of significant commercial and residential buildings in the Bay Area, including the Palace of Fine Arts .

The home’s current owners have enhanced the Tudor drama with glossy black paint and artistic design elements.

Jacob Elliot

Later McSweeny would go on to form his own firm. Along with this home, other notable buildings to McSweeny’s credit are 1200 California and St Mary’s Cathedral on Gough, the latter of which he served as part of collaborative team to create and construct.

Marble, leaded glass, iron and wood add drama while glass lets in natural light.

Jacob Elliot

The grandeur of those buildings is clearly present in 2500 Divisadero, with its classic Tudor craftsmanship. hand-carved woodwork; hand-laid stone and brick; dramatic arches, peaks, beams, built-ins and embellishments; all of these features are still present.

The kitchen is large and equipped with high-end appliances. French doors open to patio.

Jacob Elliot

But the plethora of famous owners have kept the six-bedroom, five full bathoom and three half-bathroom abode current with modern day luxury.

The outdoors are as luxe as the indoors, as evidenced by this patio and fire ring, surrounded by trees.

Jacob Elliot

The home has illustrious history. Before it was built, its location was a backdrop for the 1924 the Buster Keaton silent movie, “The Navigator.” Once the home was built, its original owners were the Bissinger family: Marjorie Walter Bissinger was the founder of the Asian Art Museum.

The home’s office has it’s own hearth as well as built-in bookshelves.

Jacob Elliot

The home has also housed the Canadian Consulate, and has featured in San Francisco’s Decorator Showcase. Previous owners and philanthropists Jeff and Laurie Ubben used the home to host fund raisers for a variety of causes. At one point, Martha Stewart stayed in the upper floor guest room while she and Jeff Ubben worked together.

A very dramatic formal dining room is warmed by an oversized fireplace.

Jacob Elliot

The current sellers are Mike Depatie, financier and former CEO of Kimpton Hotels and his wife Holly, an interior designer. Holly Depatie’s design sensibilities adorn the home’s interior.

This bathroom with its unique wall paper is light-filled and spacious.

Jacob Elliot

“The house itself inspired me with its rich history, grand entrance, extraordinary hand-carved wood, custom ironwork, and gorgeously proportioned rooms,” Holly Depatie told SFGATE. “Because of the house’s connection to the visual arts I wanted it to exude a sense of dignified drama, a grown-up modern aesthetic that embraced both its glorious past and its most relevant place in the present as one of the great San Francisco houses. “

This bedroom features built-ins for seamless storage.

Jacob Elliot

The primary bedroom features bay window looking out over the lovely views.

Jacob Elliot

In the Depatie family’s hands, this home has continued to serve philanthropic causes as well as play host to a plethora of distinguished guests. Whoever buys the property next will enjoy almost a hundred years of history included with the sale.

The home gym is fully equipped.

Jacob Elliot

Anna Marie Erwert writes from both the renter and new buyer perspective, having (finally) achieved both statuses. She focuses on national real estate trends, specializing in the San Francisco Bay Area and Pacific Northwest. Follow Anna on Twitter: @AnnaMarieErwert.

The post Former CEO of Kimpton Accommodations lists historic mansion in San Francisco’s Pacific Heights for $16M appeared first on Los Gatos News And Events.

This week, Leslie Stretch, CEO of customer experience software company Medallia, will list the Russian Hill home he bought with his wife Heather just before the pandemic for exactly what they paid for it: $20 million.

Listing agent Nina Hatvany of Compass gave TRD an exclusive first peek of the five-bedroom house, which includes a separate guest apartment one level below the main entrance. The home’s centerpiece is a floating helix-shaped limestone staircase with hand-forged railings circling a three-story Venetian glass light fixture hanging from a central skylight. There’s also a walnut-clad elevator that services all floors.

(Lunghi Studios)

The chandelier alone was rumored to cost $1 million and is an indication of the high-end finishes throughout the home, Hatvany said.

The house was built in 2013 by hedge fund manager Chris Hansen, according to public records. It has six floors plus a bay view roof deck just around the corner from Lombard’s “crookedest” street. The 10,000-square-foot home at 2626 Larkin Street was the biggest residential sale in the neighborhood when it sold at the end of January in 2020 for $2,000 a square foot, according to Redfin. It would be the biggest Russian Hill single-family sale of 2022 thus far if it sells for anywhere close to that amount, although the combined $29 million paid for a pair of penthouse suites owned by former secretary of state George Shultz in July is the bigger overall neighborhood residential sale.

Hatvany, who also represented the Stretches when they bought the home from Hansen in 2020, said her clients are selling now because the youngest of their four children has gone off to college and they are moving to a smaller pied a terre in the city. They also purchased several “spectacular” secondary homes during the pandemic, she said.

They made only minor decorative changes to the property during their two-plus years there, but spent hundreds of thousands of dollars upgrading the smart home features of the property, such as the AV system and light switches, she said. They also added two car lifts to make room for five cars in the three-car garage.

Otherwise the home is much as it appeared when they bought it in January 2020, she said, with “glowing” lime plaster walls, french white oak floors and a glass wall off the kitchen-family room that leads out to a backyard with a pizza oven, quartz stone patio and a fireplace bookended by two bronze fountains. The back of the home overlooks the garden, while the front, including the fourth-floor primary suite and fifth-floor family room, has northwest views of the bay. Both have decks to take in the views, and there’s also a panoramic view roof deck with a fire pit.

Even with the SF luxury market seeing millions in price cuts, Hatvany said the home is priced to bring in high-end buyers who she said are still actively house hunting despite the slower market.

“We have other houses on the market in the $18 [million] to $25 million range, and not one of them is as done as this house is,” she said.

Most of those properties are in Pacific and Presidio Heights, which Hatvany said are still tops for high-net-worth individuals with young families, given the proximity to parks and prestigious private schools. The Larkin home’s buyer may not be someone with “masses of children,” since it has a “more sophisticated feel,” Hatvany said, but otherwise she expects it to draw the same well-heeled crowd of house hunters to its “Pacific Heights- ish” location.

“It’s as close to Pacific Heights as you can be on Russian Hill,” she said.

Contact Emily Landes

The post Tech CEO Lists San Francisco residence with $1 million chandelier appeared first on Los Gatos News And Events.

With a storied, celebrity past and almost a century of careful preservation paired with with high-end, careful renovation, 2500 Divisadero is a San Francisco legend. You could write the next chapter for this historic mansion, on the market now for $15.995 million.

This 9,125 square-foot home was built in 1933 by locally renowned architect Angus McSweeny, a partner in Willis, Polk, and Company, an architectural partnership that produced hundreds of significant commercial and residential buildings in the Bay Area, including the Palace of Fine Arts .

The home’s current owners have enhanced the Tudor drama with glossy black paint and artistic design elements.

Jacob Elliot

Later McSweeny would go on to form his own firm. Along with this home, other notable buildings to McSweeny’s credit are 1200 California and St Mary’s Cathedral on Gough, the latter of which he served as part of collaborative team to create and construct.

Marble, leaded glass, iron and wood add drama while glass lets in natural light.

Jacob Elliot

The grandeur of those buildings is clearly present in 2500 Divisadero, with its classic Tudor craftsmanship. hand-carved woodwork; hand-laid stone and brick; dramatic arches, peaks, beams, built-ins and embellishments; all of these features are still present.

The kitchen is large and equipped with high-end appliances. French doors open to patio.

Jacob Elliot

But the plethora of famous owners have kept the six-bedroom, five full bathoom and three half-bathroom abode current with modern day luxury.

The outdoors are as luxe as the indoors, as evidenced by this patio and fire ring, surrounded by trees.

Jacob Elliot

The home has illustrious history. Before it was built, its location was a backdrop for the 1924 the Buster Keaton silent movie, “The Navigator.” Once the home was built, its original owners were the Bissinger family: Marjorie Walter Bissinger was the founder of the Asian Art Museum.

The home’s office has it’s own hearth as well as built-in bookshelves.

Jacob Elliot

The home has also housed the Canadian Consulate, and has featured in San Francisco’s Decorator Showcase. Previous owners and philanthropists Jeff and Laurie Ubben used the home to host fund raisers for a variety of causes. At one point, Martha Stewart stayed in the upper floor guest room while she and Jeff Ubben worked together.

A very dramatic formal dining room is warmed by an oversized fireplace.

Jacob Elliot

The current sellers are Mike Depatie, financier and former CEO of Kimpton Hotels and his wife Holly, an interior designer. Holly Depatie’s design sensibilities adorn the home’s interior.

This bathroom with its unique wall paper is light-filled and spacious.

Jacob Elliot

“The house itself inspired me with its rich history, grand entrance, extraordinary hand-carved wood, custom ironwork, and gorgeously proportioned rooms,” Holly Depatie told SFGATE. “Because of the house’s connection to the visual arts I wanted it to exude a sense of dignified drama, a grown-up modern aesthetic that embraced both its glorious past and its most relevant place in the present as one of the great San Francisco houses. “

This bedroom features built-ins for seamless storage.

Jacob Elliot

The primary bedroom features bay window looking out over the lovely views.

Jacob Elliot

In the Depatie family’s hands, this home has continued to serve philanthropic causes as well as play host to a plethora of distinguished guests. Whoever buys the property next will enjoy almost a hundred years of history included with the sale.

The home gym is fully equipped.

Jacob Elliot

Anna Marie Erwert writes from both the renter and new buyer perspective, having (finally) achieved both statuses. She focuses on national real estate trends, specializing in the San Francisco Bay Area and Pacific Northwest. Follow Anna on Twitter: @AnnaMarieErwert.

The post Former CEO of Kimpton Inns lists historic mansion in San Francisco’s Pacific Heights for $16M appeared first on Los Gatos News And Events.

Bentonville, Arkansas

Getty Images

The number of people leaving the Bay Area jumped 21% from March 2020 and September 2021, according to a report from University of California researchers. We talk to one man who left about why he did it. (Thinking of ditching your pricey city too? Check out the lowest mortgage rates you can get here now.)

Life as a CEO in San Francisco became increasingly stressful for Phil Libin, founder of the app mmhmm and former CEO and executive chairman of software company Evernote. After 15 years of city living, Libin decided it was time to wait out COVID-19 somewhere peaceful. So he packed his bags, told all of his employees they could work virtually forever and headed east to Bentonville, Arkansas — a place he’d passed through once or twice before, that’s known for its artsy vibe, beautiful outdoors and as the headquarters of Walmart.

“I thought I’d go somewhere for a few months, so I got an Airbnb and then decided to stay,” says Libin, who hasn’t looked back on leaving the tech capital. The thing he misses the least? Traffic. “In San Francisco, I was Ubering everywhere. I looked back at my calendar and realized I was spending almost three hours every day in a car, going to the office or from meeting to meeting,” says Libin. Now, he works from home, or a few local places within walking distance. “My life here feels much more integrated. Things are much cheaper and money goes much further,” says Libin.

He has a point: According to Realtor.com, the median sales price of a home is just over $400,000, compared to $1.5 million in San Francisco. And overall San Francisco is 147% more expensive than Bentonville, according to Sperling’s Best Places, with home prices being the biggest factor in that.

Phil Libin

While in San Francisco, Libin thought he had a high standard of living – “I was the CEO and I had a pretty good quality of life because I spent a lot of money,” he says – but he says his standard of living in Bentonville is actually much higher. “I have a higher quality of life and 100% of the people that work with me could afford to live the way I am,” says Libin. (Libin lets all of the mmhmm employees live wherever they want, and he says that about half of them who were in the Bay Area ended up moving.) “They can afford to eat at the same restaurants and be members of the same clubs, says Libin.

Now, instead of living in an overpriced condominium, Libin has bought land and is planning to build a house. “I was in SF a few weeks ago for the first time in a year and I was shocked by what I used to put up with. I had forgotten about sitting in traffic. I would sit in the car for 90 minutes all the time and I thought it was okay. I never want to ask someone to do that,” says Libin.

Of course, the restaurants and culture of San Francisco are hard to beat, but it’s easy enough to travel from Bentonville, Libin says. “There are direct flights … It’s actually easier to fly domestically from here than SF because the airport is smaller and there’s no traffic. If I have to fly internationally to Asia or Europe, it adds a hop, but it’s worth it,” says Libin.

The post ‘I used to be shocked by what I used to place up with.’ Why this CEO left San Francisco after 15 years for Bentonville, Arkansas, the place the median residence prices nearly $400K appeared first on Los Gatos News And Events.

Matthew Ros

→ The ouster of for­mer Im­munomedics ex­ec Us­ama Ma­lik cre­at­ed a CEO open­ing at Fore Bio­ther­a­peu­tics, which is tak­ing aim at BRAF mu­ta­tions fol­low­ing a re­brand last year. Matthew Ros has now stepped up to the tee box as CEO and a mem­ber of the board af­ter Ma­lik was em­broiled in an in­sid­er trad­ing scan­dal dur­ing his time at Im­munomedics that he chose to ad­dress in a rather cryp­tic LinkedIn post in De­cem­ber. A 17-year Bris­tol My­ers Squibb vet, Ros left Sanofi Gen­zyme in 2016 to be­come COO of Epizyme, where he had since been chief strat­e­gy and busi­ness of­fi­cer. Fore Bio, once known as di­ag­nos­tics com­pa­ny Nov­el­lus­Dx and chaired by for­mer Sanofi ex­ec Di­eter Weinand, is in a Phase I/IIa tri­al with its lead can­di­date FORE8394.

Brad Mar­gus

→ Brad Mar­gus is out as CEO of Take­da CNS spin­out Cere­vance, and Craig Thomp­son stands at the ready to take his place. Mar­gus will slide in­to the ex­ec­u­tive chair­man post at the end of this month and hand the reins to Thomp­son, the Pfiz­er and Mer­ck alum who got out of Dodge as chief ex­ec­u­tive of Neu­rana Phar­ma­ceu­ti­cals, where a re­cent Phase III bel­lyflop with tolperisone cast a bleak out­look on the com­pa­ny’s fu­ture. Be­fore his turn as Neu­rana’s chief, Thomp­son was pres­i­dent and CEO of An­thera Phar­ma­ceu­ti­cals and the COO at Tetraphase.

Christo­pher Sla­pak

→ Vor Bio CMO Christo­pher Sla­pak in­tends to re­tire with en­roll­ment in progress in its Phase I/IIa tri­al for acute myeloid leukemia pa­tients with high risk of re­lapse. The biotech from sci­en­tif­ic founder Sid­dhartha Mukher­jee is search­ing for can­di­dates to suc­ceed Sla­pak, the long­time Eli Lil­ly ex­ec who shed the in­ter­im med­ical chief la­bel at Vor in Ju­ly 2020. “Our plan has al­ways been for Dr. Sla­pak to build a team and in­fra­struc­ture to suc­cess­ful­ly ini­ti­ate the VBP101 clin­i­cal tri­al,” Vor chief Robert Ang said in a state­ment. “Now that we are ac­tive­ly re­cruit­ing with da­ta ex­pect­ed in the sec­ond half of 2022, we are mov­ing in­to an ex­e­cu­tion phase of the study. We have ex­pand­ed our clin­i­cal op­er­a­tions ca­pa­bil­i­ty and ex­per­tise to sup­port this ac­tiv­i­ty and now is a nat­ur­al time for this tran­si­tion.”

Joseph Ro­manel­li

→ Back in Feb­ru­ary, Mer­ck an­nounced that three peo­ple would re­place Frank Clyburn as the ex­ec left to serve as CEO at DuPont-ma­jor­i­ty owned In­ter­na­tion­al Fla­vors & Fra­grances (IFF). At the time, Mer­ck plucked up two ex­ecs from with­in, Arpa Garay (chief mar­ket­ing of­fi­cer, hu­man health) and Jan­nie Oost­huizen (pres­i­dent, Mer­ck Hu­man Health). And now, a for­mer Mer­ck ex­ec is com­ing back to take the third spot. Joseph Ro­manel­li was with Mer­ck for 25 years be­fore he took off less than a year ago to be­come CEO at Shang­hai-based Ji Xing Phar­ma­ceu­ti­cals. Dur­ing his time at Ji Xing, Ro­manel­li helped lead the com­pa­ny to ink its li­cens­ing deal with LENZ Ther­a­peu­tics for its two pres­by­opia can­di­dates.

Now, in his new role, Ro­manel­li will man­age Mer­ck’s $22 bil­lion in­ter­na­tion­al Hu­man Health busi­ness and a team of 14,000 staffers. All three ex­ecs will re­port di­rect­ly to CEO Robert Davis.

Mean­while, the found­ing CEO at Ji Xing, Pe­ter Fong, will be re­tak­ing the reins at the com­pa­ny af­ter Ro­manel­li’s de­par­ture.

Ken­neth At­tie

→ Things aren’t look­ing good over at Imara. So much so that the com­pa­ny is lay­ing off 83% of its staff at the end of this quar­ter — the com­pa­ny’s SVP and CMO Ken­neth At­tie among them — leav­ing Imara with a mea­ger 6 em­ploy­ees and a hunt for strate­gic op­tions to look at next steps. The axe fol­lows the Phase IIb flops ear­li­er this month. At­tie joined the com­pa­ny in Jan­u­ary 2021 af­ter more than a decade at Ac­celeron as VP, med­ical re­search.

Leonard Mazur

→ Citius Phar­ma­ceu­ti­cals is shak­ing things up at the top as the board has hand­ed Leonard Mazur the con­trols as CEO and chair­man. Start­ing May 1, My­ron Hol­u­bi­ak — Mazur’s pre­de­ces­sor and the for­mer pres­i­dent of Roche Lab­o­ra­to­ries — will be tran­si­tion­ing to ex­ec­u­tive vice chair­man of the board. Along with Hol­u­bi­ak, Mazur co-found­ed Leonard-Meron Bio­sciences, which merged with Citius in 2016. Mazur al­so found­ed and was CEO of Gen­e­sis Phar­ma­ceu­ti­cals.

Along with Mazur’s move, Jaime Bar­tushak will al­so be tak­ing on re­spon­si­bil­i­ties as CBO in ad­di­tion to his cur­rent CFO du­ties. Fi­nal­ly, Citius has wel­comed Michael McGuire — who de­vot­ed more than a quar­ter cen­tu­ry to Roche — as VP, pro­gram leader for an­ti-in­fec­tives. McGuire di­rect­ed the Tam­i­flu team at Roche Lab­o­ra­to­ries and joins the com­pa­ny from Melin­ta Ther­a­peu­tics, where he served as SVP com­mer­cial, gov­ern­ment af­fairs and cus­tomer en­gage­ment.

Humphrey Gard­ner

→ Ear­li­er this month, Har­bour Bio­Med en­trust­ed its CLDN18.2xCD3 bis­pe­cif­ic an­ti­body HBM7022 to As­traZeneca in a deal worth $25 mil­lion up­front, and the Shang­hai com­pa­ny has tapped Humphrey Gard­ner as CMO. The no­madic Gard­ner has held po­si­tions at nu­mer­ous com­pa­nies in the last decade, start­ing with As­traZeneca, where he was VP trans­la­tion­al med­i­cine, ear­ly clin­i­cal de­vel­op­ment. In that time pe­ri­od he’s al­so been SVP of clin­i­cal de­vel­op­ment at Karyopharm; chief, med­ical on­col­o­gy for Evelo Bio­sciences; CMO at Sil­i­con Ther­a­peu­tics; and a CMO in res­i­dence for Roivant.

Al­bert Sey­mour

→ Fac­ing a rocky road with its phenylke­tonuria gene ther­a­py that they’re try­ing to repave, Ho­mol­o­gy Med­i­cines has pro­mot­ed Al­bert Sey­mour to pres­i­dent of the com­pa­ny. Sey­mour, the chief sci­en­tist at Ho­mol­o­gy since 2016, was SVP and head of glob­al re­search and non­clin­i­cal de­vel­op­ment with Shire af­ter 13 years at Pfiz­er. The FDA put the clamps on Ho­mol­o­gy’s phenylke­tonuria tri­als in late Feb­ru­ary, with Bio­Marin run­ning in­to sim­i­lar reg­u­la­to­ry head­winds in this in­di­ca­tion a week ear­li­er.

→ The Maraganore Me­ter has resur­faced yet again as John Maraganore has been named a strate­gic ad­vi­sor at Sim­ba Gill’s Evelo Bio­sciences, along­side ex-MyoKar­dia CEO Tas­sos Gi­anakakos. A cou­ple weeks ago, we told you that the for­mer Al­ny­lam chief is on the verge of be­ing elect­ed to the board at Take­da, and Maraganore al­so racked up an­oth­er ad­vi­so­ry role at Treg biotech Aba­ta Ther­a­peu­tics.

Kel­ly Gold

→ Last sum­mer, Kel­ly Gold was pro­mot­ed to CBO and SVP of fi­nance at Camp4 Ther­a­peu­tics, the re­gR­NA biotech from Rick Young’s lab at the White­head In­sti­tute that net­ted a $45 mil­lion Se­ries A last sum­mer. This week, she proves that maybe all that glit­ters is gold, as she has been pro­mot­ed yet again, this time to CFO and SVP of fi­nance. Gold joined Camp4 in 2017 af­ter three years at Bio­gen.

→ In Michael Pari­ni’s first year as CEO of Free­line, the Lon­don biotech has notched a win in its ear­ly-stage Fab­ry dis­ease tri­al, while Pamela Foulds has suc­ceed­ed Julie Krop as CMO and Hen­ning Sten­nicke has as­sumed the role of chief sci­en­tist. This week Paul Schnei­der en­ters the fray as CFO af­ter a stint as SVP, fi­nance and op­er­a­tions with Exo Ther­a­peu­tics. Schnei­der, a for­mer fi­nance ex­ec at Aege­ri­on Phar­ma­ceu­ti­cals, was SVP, fi­nance dur­ing his three years at Case­bia Ther­a­peu­tics.

Venkat Yepuri

→ Chaired by ex-Gos­samer Bio CEO Sheila Gu­jrathi and mo­tor­ing along with a $111 mil­lion Se­ries B haul in Jan­u­ary, Cal­i­for­nia CAR-T play­er Imm­PACT Bio has ap­point­ed Venkat Yepuri as COO. Yepuri spent two decades at Am­gen, start­ing out as a glob­al strate­gic sourc­ing di­rec­tor in 2001 and ris­ing to VP, glob­al busi­ness so­lu­tions and chief pro­cure­ment of­fi­cer at the phar­ma gi­ant from 2017-21.

Math­ias Oelke

→ Math­ias Oelke has earned a pro­mo­tion to CSO at Nex­Im­mune, where Kristi Jones suc­ceed­ed Scott Carmer as CEO in late Feb­ru­ary. Oelke, a sci­en­tif­ic co-founder, was pre­vi­ous­ly SVP, pre­clin­i­cal im­munother­a­py and head of cell bi­ol­o­gy since 2017. Nex­Im­mune’s two lead as­sets— NEXI-001 for re­lapsed AML and NEXI-002 for mul­ti­ple myelo­ma — have ad­vanced to Phase I/II tri­als.

Venkat Ra­manan

→ Turn­stone Bi­o­log­ics, the Take­da vi­ral im­munother­a­py part­ner whose $80 mil­lion Se­ries D last sum­mer dwarfed its pre­vi­ous three rounds, is swing­ing the door open for Venkat Ra­manan as CFO and Joseph Camp­isi as gen­er­al coun­sel. Ra­manan held a hand­ful of fi­nance po­si­tions at Gilead and then piv­ot­ed to his lat­est stop at Seagen, where he would be pro­mot­ed to SVP of fi­nance. Camp­isi, the deputy gen­er­al coun­sel for a por­tion of his 16 years at Bris­tol My­ers, was re­cent­ly EVP, gen­er­al coun­sel and sec­re­tary with Scor­pi­on Ther­a­peu­tics.

Ras­mus Holm-Jor­gensen

→ Ras­mus Holm-Jor­gensen leads a huge cast that has ven­tured off to Acrivon Ther­a­peu­tics, Pe­ter Blume-Jensen’s bid to re­vive the old Eli Lil­ly drug prex­as­ert­ib (now known as ACR-368). Holm-Jor­gensen, Acrivon’s new CFO, spent 11 years at No­vo Nordisk and helped build Kiniksa from the ground up in 2015 as chief strat­e­gy and port­fo­lio of­fi­cer. Join­ing Holm-Jor­gensen are the fol­low­ing ex­ecs: Bruce Close (VP of qual­i­ty and com­pli­ance); James Dun­yak (VP of bio­sta­tis­tics); Joon Jung (VP and head of da­ta sci­ence); Crys­tal Mer­ca­do (glob­al head of HR); Thomas Ni­fong (head of clin­i­cal CDx op­er­a­tions); Sam Rua (VP of CDx reg­u­la­to­ry); and John van Duzer (VP of CMC).

Ehab El-Gabry

→ Roche vet Ehab El-Gabry has signed on as CMO of As­traZeneca spa­tial bi­ol­o­gy part­ner Akoya Bio­sciences, which has made sev­er­al ap­point­ments in the past year, in­clud­ing for­mer Park­er In­sti­tute for Can­cer Im­munother­a­py COO Fred­er­ic Pla. Be­fore tak­ing on this role, El-Gabry had been se­nior med­ical di­rec­tor for Per­son­al­ized Health Care So­lu­tions (PCHS) at Roche Tis­sue Di­ag­nos­tics.

Sarah Math­ieson

→ Fo­cused on he­pati­tis delta virus but boast­ing pos­i­tive re­sults with pegin­ter­fer­on lamb­da for Covid-19 last month, Eiger Bio­Phar­ma­ceu­ti­cals has scaled more lead­er­ship peaks to find chief tech­ni­cal of­fi­cer Chris Kurtz and SVP of cor­po­rate af­fairs Sarah Math­ieson. Kurtz left Gilead, where he was head of com­mer­cial API man­u­fac­tur­ing, to be­come EVP of tech­ni­cal op­er­a­tions at Cidara Ther­a­peu­tics in late 2020. Mean­while, Math­ieson — a 10-year GSK alum who was the Big Phar­ma’s glob­al head of R&D com­mu­ni­ca­tions and glob­al head of com­mu­ni­ca­tions and en­gage­ment for GSK Con­sumer Health­care — was re­cent­ly the EVP, cor­po­rate com­mu­ni­ca­tions, pa­tient ad­vo­ca­cy and en­gage­ment with Adamas Phar­ma­ceu­ti­cals.

→ Aaron Os­borne has been ap­point­ed CMO and chief de­vel­op­ment of­fi­cer at Nanoscope Ther­a­peu­tics, a Dal­las biotech de­vel­op­ing gene ther­a­pies for reti­nal dis­eases, join­ing Anil Lal­wani (VP of CMC and qual­i­ty) and Jared Stephens (VP of strat­e­gy and BD) as the newest ex­ecs. At Ad­verum, Os­borne most re­cent­ly served as CMO, and he has al­so held po­si­tions at Genen­tech, Al­con, No­var­tis and Bay­er.

Vir­ginia Casadas

→ Got­ta have Faeth: Thomas Strack is on board as CMO of Faeth Ther­a­peu­tics, while Vir­ginia Casadas joins the San Fran­cis­co-based squad as head of clin­i­cal op­er­a­tions. Strack had led clin­i­cal de­vel­op­ment at Mol­e­c­u­lar Tem­plates, and Casadas — a Pfiz­er and No­var­tis vet — is the ex-di­rec­tor, clin­i­cal op­er­a­tions at Vir Biotech­nol­o­gy. The sci­en­tif­ic co-founders at the AI-dri­ven can­cer me­tab­o­lism com­pa­ny in­clude Lewis Cant­ley, Sid Mukher­jee and Can­cer Re­search UK’s Karen Vous­den.

→ Tread­well Ther­a­peu­tics has brought on JD Mow­ery as COO. Mow­ery makes his way to the com­pa­ny with plen­ty of ex­pe­ri­ence un­der his belt from his times at Genen­tech, Lon­za, Juno/Cel­gene and AGC Bi­o­log­ics. Dur­ing his most re­cent stint at AGC, Mow­ery served as EVP, US op­er­a­tions.

→ Austin-based Maxwell Bio­sciences has ush­ered in Ed­ward Rud­nic as COO. Rud­nic was the founder, chair­man and CEO of Mid­dle­Brook Phar­ma­ceu­ti­cals and has pre­vi­ous ex­pe­ri­ence in stints at Shire, Vivre­on Bio­sciences, QRx Phar­ma, Union­Bridge Man­age­ment, Mer­ck and Bris­tol My­ers.

→ Just af­ter pulling in Dan Devine as CBO and gen­er­al coun­sel last week, Aussie biotech Vaxxas is now wel­com­ing aboard Scott Fry as COO. Fry hails from El­lume where he served as chief op­er­a­tions of­fi­cer and was re­spon­si­ble for the de­vel­op­ment and com­mer­cial­iza­tion of rapid tests for de­tect­ing dengue, in­fluen­za A, in­fluen­za B, group A strep­to­coc­cus, res­pi­ra­to­ry syn­cy­tial virus and Covid-19.

Lu­cas Vi­tale

→ A month re­moved from Sid­dhartha Ka­dia’s ap­point­ment as CEO, dig­i­tal cell bi­ol­o­gy play­er Berke­ley Lights has re­cruit­ed Lu­cas Vi­tale as chief hu­man re­sources of­fi­cer. Vi­tale just had a short stay as SVP of hu­man re­sources at Are­na Phar­ma­ceu­ti­cals, part of what Pfiz­er hopes is a con­tin­ued M&A blitz that re­cent­ly in­clud­ed the $525 mil­lion buy­out of Re­Vi­ral. He al­so climbed up the ranks to fin­ish his sev­en years at Nu­Va­sive as chief hu­man re­sources of­fi­cer.

→ An­oth­er Are­na vet has cho­sen a dif­fer­ent path: Patrick Mal­loy is now SVP, in­vestor re­la­tions and strate­gic com­mu­ni­ca­tions for Lu­ca Santarel­li at Vec­tivBio. Af­ter 16 years at Acte­lion, Mal­loy joined Are­na as se­nior di­rec­tor, glob­al mar­ket de­vel­op­ment for its PAH drug ra­linepag, earn­ing a pro­mo­tion to VP, in­vestor re­la­tions and strate­gic com­mu­ni­ca­tions.

Sami­ra Shaikhly

→ Third Rock-backed re­gen­er­a­tive play Am­bys Med­i­cines is bring­ing in a new duo to its lead­er­ship team with the ap­point­ments of Sami­ra Shaikhly as chief hu­man re­sources of­fi­cer and John McK­eon as VP of fi­nance. Shaikhly spent 15 years over at Gilead — cul­mi­nat­ing in her most re­cent role as glob­al head of hu­man re­sources, cor­po­rate func­tion — be­fore mak­ing her way to Am­bys. Mean­while, McK­eon hops aboard af­ter serv­ing as se­nior di­rec­tor of fi­nan­cial plan­ning and analy­sis at Al­lakos and has oth­er stints at Jaguar Health, Bio­Marin, Avinger and Genen­tech un­der his belt.

→ ProMIS Neu­ro­sciences has reeled in Lar­ry Alt­stiel as CMO. Alt­stiel tacks on this role to his cur­rent re­spon­si­bil­i­ties as part time CMO at Pin­teon Ther­a­peu­tics. Ear­li­er in his ca­reer, Alt­stiel served as VP and head of neu­ro­science clin­i­cal re­search at Pfiz­er.

→ Boul­der, CO-based Enve­da Bio­sciences has made room on its ex­ec team for Robert Buck­ley as chief peo­ple of­fi­cer. Buck­ley most re­cent­ly served as chief peo­ple of­fi­cer at Rain­Fo­cus and has pri­or ex­pe­ri­ence at Mi­no­va In­ter­na­tion­al, eBay, Gen­er­al Elec­tric and Thumb­tack.

Christo­pher Verni

→ Vig­il Neu­ro­science — which closed a $98 mil­lion IPO back in Jan­u­ary to fu­el its two ex-Am­gen TREM2 ag­o­nists — has wel­comed aboard Christo­pher Verni as gen­er­al coun­sel and Mary This­tle to its board of di­rec­tors. Verni most re­cent­ly served as SVP, gen­er­al coun­sel and chief in­tel­lec­tu­al prop­er­ty of­fi­cer at Sarep­ta Ther­a­peu­tics. Pri­or to that, Verni had gigs at ARI­AD Phar­ma­ceu­ti­cals, Gen­zyme and Pfiz­er.

Mean­while, this isn’t This­tle’s first board ap­point­ment as she sits on a num­ber of boards in­clud­ing Alaunos Ther­a­peu­tics, Ho­mol­o­gy Med­i­cines, En­tra­da Ther­a­peu­tics, En­terome and Co­coon Bio. This­tle cur­rent­ly serves as spe­cial ad­vi­sor at the Bill & Melin­da Gates Med­ical Re­search In­sti­tute and be­fore that, served as COO of Di­men­sion Ther­a­peu­tics. This­tle al­so has held roles at Ul­tragenyx, Cu­bist Phar­ma­ceu­ti­cals, PerkinElmer and Vi­a­cell.

Gabrielle Poiri­er

→ Com­pu­ta­tion­al chem­istry out­fit Nim­bus Ther­a­peu­tics has wel­comed two new ex­ecs while pro­mot­ing an­oth­er: VP of clin­i­cal de­vel­op­ment Bhaskar Sri­vas­ta­va, a vet­er­an of J&J’s Janssen, has been el­e­vat­ed to SVP. Gabrielle Poiri­er (VP, clin­i­cal op­er­a­tions) just held the same post at an­tibi­otics biotech En­ta­sis, and the for­mer clin­i­cal op­er­a­tions VP at Pro­teosta­sis Ther­a­peu­tics was al­so an as­so­ciate di­rec­tor at Iron­wood and Alex­ion. Zak Huang (VP, reg­u­la­to­ry af­fairs) spent 11 years be­fore mov­ing on to CSL Behring to be­come head of glob­al prod­uct reg­u­la­to­ry strat­e­gy and lat­er the head of Chi­na R&D.

François Bi­nette

→ Enochi­an Bio­Sciences has ap­point­ed François Bi­nette as EVP for R&D. Bi­nette, who once worked in re­gen­er­a­tive med­i­cine at J&J, most re­cent­ly served as SVP of prod­uct de­vel­op­ment at Lin­eage Cell Ther­a­peu­tics. Ear­li­er this month, the Los An­ge­les-based de­vel­op­er of cell ther­a­pies for HIV and can­cer brought on long­time Pfiz­er vet Greg Duczyn­s­ki as SVP for clin­i­cal op­er­a­tions.

Ka­te­ri­na Left­heris

→ In its first Peer Re­view ap­pear­ance since COO Niru­pa­ma Sub­ra­man­ian joined the team, Third Rock-backed Rheos Med­i­cines has lined up Ka­te­ri­na Left­heris as SVP of drug dis­cov­ery and Nabil Ud­din as VP of strat­e­gy and busi­ness de­vel­op­ment. Left­heris, a Bris­tol My­ers alum, com­pletes a near­ly five-year run as VP of chem­istry at Pli­ant Ther­a­peu­tics, while Ud­din has ex­it­ed the stage at Con­cert Phar­ma­ceu­ti­cals af­ter his time as VP of cor­po­rate de­vel­op­ment.

Ur­vashi Pa­tel

→ Gam­ma delta T cell out­fit IN8bio has two ap­point­ments that we didn’t get to dur­ing the short week last week: Ur­vashi Pa­tel has tak­en over as VP, reg­u­la­to­ry af­fairs, and Stacey Bilin­s­ki is the new VP, clin­i­cal op­er­a­tions. Pa­tel, who comes to IN8bio from her role as VP of reg­u­la­to­ry and qual­i­ty sys­tems at Wind­MIL Ther­a­peu­tics, al­so held po­si­tions at Janssen, Elan Phar­ma­ceu­ti­cals and Genen­tech. Bilin­s­ki most re­cent­ly served as glob­al se­nior di­rec­tor, op­er­a­tions at Tai­ho On­col­o­gy.

Su­san Flint

→ Alzheimer’s biotech Alzheon out of Fram­ing­ham, MA has di­aled up three new staffers: Su­san Flint (VP of clin­i­cal op­er­a­tions) al­so led clin­i­cal op­er­a­tions at Swedish biotech Wil­son Ther­a­peu­tics, which Alex­ion pur­chased for $855 mil­lion sev­er­al years ago; Patrick Kess­lak (VP of clin­i­cal de­vel­op­ment & med­ical af­fairs) is an Am­gen and Al­ler­gan vet who was re­cent­ly the se­nior di­rec­tor, clin­i­cal de­vel­op­ment for Re­vance Ther­a­peu­tics; and Er­wan de Nau­rois (VP of fi­nance) has left the role of se­nior di­rec­tor, fi­nan­cial plan­ning & analy­sis at Flag­ship Pi­o­neer­ing.

→ Boston-based Aileron Ther­a­peu­tics, whose lead pro­gram AL­RN-6924 fo­cus­es on p53-mu­tat­ed can­cers, has en­list­ed Christo­pher Zergebel as VP, pro­gram man­age­ment and clin­i­cal op­er­a­tions. So ends a long as­so­ci­a­tion with Tai­ho On­col­o­gy, where Zergebel was re­cent­ly VP, R&D ser­vices and VP, project man­age­ment.

Ashok Marín

→ With its lead bis­pe­cif­ic an­ti­body can­di­date ISB 1342 in Phase I for re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma, Glen­mark spin­out Ich­nos Sci­ences has se­lect­ed Ashok Marín as gen­er­al coun­sel. Marín held the role of chief le­gal of­fi­cer for four short months at Rafael Hold­ings af­ter a year-long stay at Gilead as as­so­ciate gen­er­al coun­sel. He’s al­so been Mallinck­rodt’s VP, com­pli­ance & chief pri­va­cy of­fi­cer.

→ Dirk Sauer, who re­tired last year af­ter 31 years at No­var­tis, has been added to the board of di­rec­tors at Bal­ti­more-based Gray­bug Vi­sion, suc­ceed­ing Ger­ard Ca­gle. From 2011-21, Sauer was in charge of No­var­tis’ oph­thal­mol­o­gy de­vel­op­ment unit.

John Scar­lett

→ Geron pres­i­dent and CEO John Scar­lett will re­tire from the board of di­rec­tors at South San Fran­cis­co can­cer biotech Cy­tomX when stock­hold­ers meet on June 15. Scar­lett had served on the board since June 2016.

→ US-Aus­tri­an im­munother­a­py biotech Hookipa Phar­ma has elect­ed Tim Reil­ly to the board of di­rec­tors. Af­ter an 18-year run at Bris­tol My­ers end­ed in 2021, Reil­ly made the leap to HotSpot Ther­a­peu­tics as their chief de­vel­op­ment of­fi­cer.

→ Roque­fort Ther­a­peu­tics is ush­er­ing in Si­mon Sin­clair as non-ex­ec­u­tive di­rec­tor to its board. Sin­clair has held a num­ber of roles at J&J and Mer­ck. Cur­rent­ly, Sin­clair serves as chief safe­ty of­fi­cer at Reckitt Benckiser Group.

The post Transferring on from Usama Malik’s insider buying and selling imbroglio, Fore resets on the high; Takeda spinout turns to Neurana CEO to cleared the path – Endpoints Information appeared first on Los Gatos News And Events.

Ukraine’s 41 and a half million people are well aware of the military buildup along its eastern border with Russia. The threat is a big concern for San Francisco’s JustAnswer. One-third of its workforce — 252 people — live in Ukraine.

“A lot of our engineering, a lot of our critical functions are done there,” said CEO Andy Kurtzig. “So it’s very scary, and even more scary on a personal level because these are all our friends.”

We connected with Nadya Semen, JustAnswer’s country manager based in Lviv near the border with Poland. She believes Russia has already initiated cyberattacks.

If you’re on the ABC7 News app, click here to watch live

“We are experiencing a set of cyberattacks on different websites and banking system and some governmental websites were down. So it’s weird,” she said.

She has an 18-year-old son and an 11-year-old daughter. Their safety has already been threatened.

“Two times during class for weeks, I had to pick up my kid from school because someone called that there is a bomb in the school,” she said.

JustAnswer has developed its own action plan. It puts the current threat level at moderate to high because of some military activities. As the threat rises to high and to realized threat, that will initiate more action to protect its workers.

RELATED: Biden says US has reason to believe Russia ‘intends to attack’ Ukraine: ‘I’m convinced’

“We are moving people from the east to the west as we speak and give them time of and putting them up in hotels and then actively helping them move across the country from the more dangerous parts of Ukraine,” CEO Kurtzig said.

Stress levels are rising. School children are drilled about evacuating to shelters, which frightened Nadya’s daughter.

VIDEO: Bay Area Ukrainians worried about Russian invasion, many praying for peace

“She was stressed by that, so she was asking me, ‘When are we supposed to expect the real worst to come here? So why are Russians doing this? Why people are starting to worry? I really can be killed now?'”

Andy Kurtzig and his family lived in Ukraine for six months in 2019, prior to the Russian threat. The people and the culture of Ukraine captivated them.

“We love them,” he said. “We’ve been working with them for a long time, and we’re committed to them.”

As part of that commitment, Kurtzig said he has made arrangements to be able to pay them from Poland, even with cryptocurrency if necessary. He is also supplying them with satellite phones and alternatives if the internet or electricity is lost.

Copyright © 2022 KGO-TV. All rights reserved.

The post San Francisco CEO works to guard lots of of staff in Ukraine amid menace of Russia assault appeared first on Los Gatos News And Events.

SAN FRANCISCO & CARROLLTON, Texas – (BUSINESS WIRE) – Golden Gate Capital, a leading private equity investment firm, and All My Sons Moving & Storage founder and CEO Robert Peterson today announced the recapitalization of All My Sons, a leading provider of world-class moving and storage services . Mr. Peterson will continue to lead the company from its headquarters in Carrollton, TX and remain a significant shareholder. Financial terms were not disclosed.

All My Sons was founded in 1992 and is a family business with almost 30 years of moving experience. The company operates 75 locations in 29 states and focuses primarily on local removals with professional and efficient moving services tailored to a wide range of customer needs. All My Sons’ business model differs through an industry-leading technology platform that drives lead generation, security and operational efficiency, and enables the company to deliver a highly personalized customer experience.

Mr. Peterson said, “Thanks to our dedicated team and a successful partnership with Sterling Investment Partners, All My Sons has continued its rapid growth over the past decade and established itself as the most effective and efficient provider of moving and storage services in the United States.” Conditions. With proven successful partnerships with founder-run companies, Golden Gate Capital is the perfect partner to accelerate our growth and further develop our world-class customer experience. We look forward to working with the Golden Gate Capital team to take advantage of the opportunities that arise. ”

Mike Montgomery, Managing Director at Golden Gate Capital, said, “We are very excited to be working with Robert and the All My Sons team. They have built a market leading platform backed by proprietary systems and processes that deliver an unparalleled customer experience. With clear leadership in the 54 markets it serves, All My Sons is well positioned to continue to gain market share in a highly fragmented market as it remains true to its mission to transport customers safely, comfortably and confidently. We look forward to helping the company seize the many opportunities that lie ahead. ”

Neale Attenborough, Operating Partner at Golden Gate Capital, commented, “We have great respect for Robert and his longstanding leadership team. Driven by an entrepreneurial spirit and commitment to constant innovation, they have built a huge company with significant growth opportunities, including new entries and expansion into adjacent categories. We look forward to leveraging our expertise in partnering with strong, founder-led companies to support the next era of All My Sons growth. ”

Charles Santoro, Managing Partner and Founder of Sterling Investment Partners, added, “We are proud of our partnership with Robert and his outstanding team, who have positioned the company well to continue its strong momentum. We are confident that the company has a very bright future and that it will continue to be successful in partnership with Golden Gate Capital. ”

Ropes & Gray LLP and Nob Hill Law Group PC served as legal advisor to Golden Gate Capital. Norton Rose Fulbright acted as legal advisor and William Blair & Company LLC acted as chief financial advisor to All My Sons. Piper Sandler Companies and Harris Williams LLC also served as advisors to the company.

About All My Sons Moving & Storage

For nearly 30 years, All My Sons Moving & Storage has built a solid reputation and won the trust of its customers. The company offers full-service removals for customers and companies on site and across national borders. The first-class services include moving, wrapping furniture with quilts and their dismantling and reassembly, packing and unpacking.

About Golden Gate Capital

Golden Gate Capital is a San Francisco-based private equity investment company with accumulated committed capital of over $ 19 billion. Golden Gate Capital’s principles have a long and successful history of investing in a wide variety of industries and types of transactions, including going private, business disposals and recapitalizations, and debt and public equity investments. Notable multi-unit consumer investments sponsored by Golden Gate Capital include Tidal Wave Auto Spa, The Learning Experience, and Mavis Express Tire Services. More information is available at www.goldengatecap.com.

About Sterling Investment Partners

Sterling Investment Partners is a private equity firm that has invested in and built medium-sized companies for over 30 years with a highly experienced, coherent team of senior investment professionals. Sterling focuses on value-adding sales and business services, acquiring companies that it believes have strong, sustainable competitive advantages and significant value opportunities. Throughout its history, Sterling has completed over 180 transactions with a gross deal value of $ 19.4 billion. www.sterlinglp.com

The post Golden Gate Capital Companions With Founder and CEO Robert Peterson on Recapitalization of All My Sons Transferring & Storage appeared first on Los Gatos News And Events.

SAN FRANCISCO, Oct 07, 2021 (GLOBE NEWSWIRE) – The Federal Home Loan Bank of San Francisco (FHLBank San Francisco) congratulates President and CEO Teresa Bryce Bazemore on her recognition as one of the most influential women in the Bay Area economy for 2021 by the San Francisco Business Times. Bazemore and the other honorees will be celebrated at a virtual event today.

The annual list recognizes the leadership and accomplishments of women in a wide cross-section of industries, and Bazemore has wasted no time driving change in her industry since joining FHLBank San Francisco last March. “I want to thank the San Francisco Business Times for this recognition,” said Bazemore. “And to extend my congratulations to all of the amazing, inspiring women on the Influential Women list in 2021. I feel honored to be in such a company. “

Bazemore is a pioneer in the financial industry and a seasoned executive with over 25 years of leadership experience building and running mortgage insurance and service companies. Bazemore was appointed to her role at FHLBank San Francisco, effective March 15, and has been a driving force in responding to the economic impact of the pandemic and the differences it highlighted. With a passion for creating wealth for all, Bazemore is focused on leveraging the bank’s existing affordable housing, first home buyers and economic development grant programs, as well as brand new initiatives to serve in the communities of the bank and its member financial institutions.

“I am thrilled to come to work every day and work with my team to empower our members to best serve their customers and communities,” said Bazemore. “With the economic shocks and upheavals of the pandemic behind us, the bank’s business operations and community support initiatives need to be even more resilient to fulfill our mission to make all of our communities more equitable and resilient.”

To that end, Bazemore followed the recently announced collaboration between FHLBank San Francisco and the Urban Institute that focused on the home ownership gap between black and white. The two-year, $ 1.5 million research and product development initiative called Racial Equity Accelerator for Homeownership aims to address some of the most persistent challenges in closing racial home ownership and wealth accumulation challenges. She is also committed to helping the bank play a bigger role in supporting infrastructure projects that improve the quality of life for residents in its Arizona, California and Nevada offices.

Bazemore has paved the way for women in the financial services industry throughout her career and serves as an important role model for emerging generations. She draws on her wealth of experience in the home finance industry to find workable solutions to complex and ongoing challenges facing the bank’s member lenders and the customers and communities they serve. Prior to her appointment to FHLBank San Francisco, she rose to the position of President of Radian Guaranty. Prior to joining Radian, she served as general counsel and in executive positions at Nexstar Financial Corporation and in the mortgage banking business of Bank of America. As a former member of the Board of Directors of FHLBank Pittsburgh, Bazemore currently serves on the boards of First Industrial Realty Trust, Inc. and T. Rowe Price Funds. Her career roles have included serving on the Federal Reserve Bank of Philadelphia Economic Advisory Board, Fannie Mae National Advisory Board, and the Federal Reserve Consumer Advisory Board.

Via the Federal Home Loan Bank of San Francisco

The Federal Home Loan Bank of San Francisco is a member-operated cooperative that helps local lenders in Arizona, California, and Nevada build strong communities, create opportunities, and change lives for the better. The tools and resources that we make available to our member financial institutions – commercial banks, credit unions, industrial credit companies, savings institutions, insurance companies and financial institutions for community development – promote home ownership, expand access to high-quality housing, establish or support small businesses and revitalize entire neighborhoods. Together with our members and other partners, we make the communities we serve more vibrant and resilient.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d88ba855-3269-488d-bbab-73ef8e546e2a.

The post FHLBank San Francisco CEO Teresa Bryce Bazemore Named One appeared first on Los Gatos News And Events.